The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casolaro, V.
Right arrow Articles by Marone, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casolaro, V.
Right arrow Articles by Marone, G.

The Journal of Immunology, Vol 151, Issue 10 5563-5573, Copyright © 1993 by American Association of Immunologists


ARTICLES

In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils

V Casolaro, G Spadaro, V Patella and G Marone
Division of Clinical Immunology and Allergy, University of Naples Federico II, School of Medicine, Italy.

We investigated whether cyclosporin A (CsA) in vivo exerts anti- inflammatory effects by inhibiting IgE- and non-IgE-dependent mediator release from human basophils. Six healthy volunteers were given oral CsA (5 mg/kg twice daily) or placebo for 5 days. Plasma CsA and basophil releasability in response to anti-IgE, FMLP, and A23187 were monitored 1 day before treatment, on alternate days during the treatment course, and 1 and 8 days after cessation of treatment. A constant plasma level of approximately 250 ng/ml CsA was obtained during CsA treatment. Basophil releasability in response to anti-IgE, FMLP, and A23187 was diminished by 20 to 60% throughout the course of CsA treatment. Placebo had no effect on basophil releasability. There was a significant correlation between plasma CsA and the decrease of histamine release induced by anti-IgE (rs = -0.66; p < 0.0005), FMLP (rs = -0.59; p < 0.001) and A23187 (rs = -0.68; p < 0.0001). In a second study, eight normal volunteers were given a single oral dose of CsA (7 mg/kg) or placebo, and plasma CsA and basophil releasability were monitored at different times thereafter. A rapid and significant reduction of histamine release induced by anti-IgE, FMLP, and A23187 paralleled a sharp increase of CsA plasma levels, which peaked at 5 h and lasted approximately 13 h. This study indicates that oral administration of CsA in normal subjects causes a rapid and significant inhibition of histamine release from basophils. This is the first evidence that in vivo administration of CsA can modulate the release of proinflammatory mediators from basophils obtained ex vivo.


This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
L. N. KHAN, O. M. KON, A. J. MACFARLANE, Q. MENG, S. YING, N. C. BARNES, and A. BARRY KAY
Attenuation of the Allergen-induced Late Asthmatic Reaction by Cyclosporin A Is Associated with Inhibition of Bronchial Eosinophils, Interleukin-5, Granulocyte Macrophage Colony-Stimulating Factor, and Eotaxin
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1377 - 1382.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Patella, G. Florio, A. Petraroli, and G. Marone
HIV-1 gp120 Induces IL-4 and IL-13 Release from Human Fc{epsilon}RI+ Cells Through Interaction with the VH3 Region of IgE
J. Immunol., January 15, 2000; 164(2): 589 - 595.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Patella, A. Giuliano, J.-P. Bouvet, and G. Marone
Endogenous Superallergen Protein Fv Induces IL-4 Secretion from Human Fc{epsilon}RI+ Cells Through Interaction with the VH3 Region of IgE
J. Immunol., November 15, 1998; 161(10): 5647 - 5655.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.